NRIX Nurix Therapeutics, Inc.
AI brief AI-written, not reviewed by a person
Latest period figures show substantial quarterly revenue of 673,064,000 USD and a notable quarterly net income of 549,807,000 USD, alongside year-end cash and equivalents of 720,242,000 USD as of 2026-08-31, with year-ago and prior-period figures provided for comparison. Stockholders’ equity as of 2026-08-31 is 968,311,000 USD, while total assets reach 1,195,298,000 USD and total liabilities 226,987,000 USD. Filing context includes a 10-Q filed 2026-10-13 and an accompanying 8-K filed 2026-10-13, underscoring the most recent reporting window and accompanying disclosures.
- As of 2026-08-31, cash and equivalents are 720,242,000 USD, up from 246,960,000 USD on 2025-11-30 and 78,438,000 USD on 2025-08-31, indicating significant liquidity movement within the year. [1]
- Revenue (quarter) for 3 months to 2026-08-31 is 673,064,000 USD, compared with 6,250,000 USD for 3 months to 2026-02-28 and 7,894,000 USD for 3 months to 2025-08-31—showing a large quarterly spike in the latest period. [1]
- Net income (quarter) for 3 months to 2026-08-31 is 549,807,000 USD, contrasting with -89,535,000 USD for 3 months to 2026-05-31 and -87,174,000 USD for 3 months to 2026-02-28, indicating a swing to profitability in the latest quarter. [1]
- Total assets as of 2026-08-31 are 1,195,298,000 USD, with total liabilities of 226,987,000 USD and stockholders’ equity of 968,311,000 USD, per the same date stamps. [1][2]
- 12 months to 2025-11-30, revenue is 83,980,000 USD, and 12 months to 2025-11-30, net income is -264,457,000 USD, providing a year-over-year view that contrasts with the most recent quarterly surge. [1][2]
- Shares outstanding as of 2026-09-30 are 109,249,814, reflecting updates within the latest reporting period. [1]
- Total equity as of 2026-05-31 is 402,627,000 USD and as of 2026-02-28 is 480,893,000 USD, showing fluctuations in equity across the first half of 2026. [1]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
What the sources did not support
- No explicit annual dividend or guidance figures are provided in the sources.
- No explicit discussion of revisions or restatements beyond the numeric figures listed; qualitative analysis of drivers is not present in the cited items.
- Cross-period reconciliation details are not provided in the cited items.
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Revenue (quarter) (3 months to 2026-08-31) | 673,064,000 USD | sec-companyfacts | current | ||
| Revenue (year) (12 months to 2025-11-30) | 83,980,000 USD | sec-companyfacts | current | ||
| Net income (quarter) (3 months to 2026-08-31) | 549,807,000 USD | sec-companyfacts | current | ||
| Net income (year) (12 months to 2025-11-30) | -264,457,000 USD | sec-companyfacts | current | ||
| Operating income (quarter) (3 months to 2026-08-31) | 559,451,000 USD | sec-companyfacts | current | ||
| Operating income (year) (12 months to 2025-11-30) | -285,666,000 USD | sec-companyfacts | current | ||
| Diluted EPS (quarter) (3 months to 2026-08-31) | 4.73 USD/shares | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2025-11-30) | -3.05 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (quarter) (3 months to 2026-02-28) | -71,914,000 USD | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2025-11-30) | -249,465,000 USD | sec-companyfacts | current | ||
| Total assets (at 2026-08-31) | 1,195,298,000 USD | sec-companyfacts | current | ||
| Total liabilities (at 2026-08-31) | 226,987,000 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-08-31) | 968,311,000 USD | sec-companyfacts | current | ||
| Cash and equivalents (at 2026-08-31) | 720,242,000 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-09-30) | 109,249,814 shares | sec-companyfacts | current |
Context
No reviewed context has been published for NRIX. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add NRIX to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: NRIX.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.